Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide.

A pharmacodynamic analysis of the input-response relationship between the gonadotropin-releasing hormone antagonist antide and luteinizing hormone (LH) and testosterone concentrations is presented. A control compartmental model is developed using pharmacokinetic and pharmacodynamic data from experiments in which different short intravenous antide infusions were given to healthy male volunteers. Because of the control interdependence between serum LH and testosterone a separation principle similar to one we have used previously to analyze physiological pharmacokinetic data is used for model exploration: testosterone and LH are first modeled separately, conditioning on the other observed response. This reveals that the LH effect on testosterone depends on previous LH exposure and that LH depends not on current but on previous testosterone exposure, resulting in an LH overshoot after antide-induced suppression. Both submodels are combined into one global model, which in addition includes a model for testosterone circadian variation. This model describes the data well and can be used to predict responses for some nonstudied antide dosages. However, the sensitivity of predictions to model assumptions limits the range of valid extrapolation, and this, too, is illustrated.

[1]  K. Gordon,et al.  Single dose long-term suppression of testosterone secretion by a gonadotropin-releasing hormone antagonist (Antide) in male monkeys. , 1990, Contraception.

[2]  L B Sheiner,et al.  Semiparametric models for antagonistic drug interactions. , 1994, Journal of applied physiology.

[3]  D. Klingmüller,et al.  Gonadotropin-releasing hormone: physiological and endocrinological aspects. , 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[4]  K. Gordon,et al.  Inhibition of pituitary gonadotropin secretion by the gonadotropin-releasing hormone antagonist antide. I. In vitro studies on mechanism of action. , 1991, Endocrinology.

[5]  H. Akaike A new look at the statistical model identification , 1974 .

[6]  C. Bowers,et al.  Antide and related antagonists of luteinizing hormone release with long action and oral activity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Rogol,et al.  Operating characteristics of the male hypothalamo-pituitary-gonadal axis: pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. , 1987, The Journal of clinical endocrinology and metabolism.

[8]  A. Clark,et al.  Kinetics of testosterone metabolism in normal postmenopausal women and women with breast cancer , 1978, Steroids.

[9]  P. Conn,et al.  Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men. , 1993, Fertility and sterility.

[10]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.

[11]  A. Eshkol,et al.  Binding kinetics of the long-acting gonadotropin-releasing hormone (GnRH) antagonist antide to rat pituitary GnRH receptors. , 1994, Endocrinology.

[12]  Y. Hishikawa,et al.  Circadian rhythm of serum testosterone and its relation to sleep: comparison with the variation in serum luteinizing hormone, prolactin, and cortisol in normal men. , 1980, The Journal of clinical endocrinology and metabolism.